T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex

Circulation: Cardiovascular Imaging

Volumn 6, Issue 5, 2013, Pages 637-645

  Thompson, Richard B ^a   Chow, Kelvin ^a   Khan, Aneal ^b   Chan, Alicia ^a   Shanks, Miriam ^a   Paterson, Ian ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cardiomyopathies; CMR; Fabry disease; Hypertrophy

Indexed keywords

GADOLINIUM;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

CARDIOMYOPATHIES; CMR; FABRY DISEASE; HYPERTROPHY;

ADULT; AGED; ALBERTA; ANALYSIS OF VARIANCE; CARDIOMEGALY; CASE-CONTROL STUDIES; FABRY DISEASE; FEMALE; HEART VENTRICLES; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEX FACTORS; STROKE VOLUME; SYSTOLE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84884493018     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.113.000482     Document Type: Article

References (52)

1. Clarke JT. Narrative review: Fabry disease. Ann Intern Med. 2007; 146: 425-433. (Pubitemid 351650579)
2. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004; 110: 1047-1053. (Pubitemid 39319001)
3. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995; 333: 288-293.
4. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006; 79: 31-40. (Pubitemid 43927374)
5. Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng KH, Hsueh C, Niu DM. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009; 2: 450-456.
6. Mechtler TP, Stary S, Metz TF, De Jesús VR, Greber-Platzer S, Pollak A, Herkner KR, Streubel B, Kasper DC. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012; 379: 335-341.
7. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003; 108: 1299-1301. (Pubitemid 37174405)
8. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009; 119: 524-529.
9. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G; FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. J Med Genet. 2009; 46: 548-552.
10. Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009; 54: 1407-1424.
11. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, Shakesprere J, Kellman P, Shroff SG, Schwartzman DS, Mulukutla SR, Simon MA, Schelbert EB. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012; 126: 1206-1216.
12. Klem I, Shah DJ, White RD, Pennell DJ, van Rossum AC, Regenfus M, Sechtem U, Schvartzman PR, Hunold P, Croisille P, Parker M, Judd RM, Kim RJ. Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. Circ Cardiovasc Imaging. 2011; 4: 610-619.
13. Chow K, Flewitt J, Pagano J, Green J, Friedrich M, Thompson RB. T2-dependent errors in molli t1 values: simulations, phantoms, and in-vivo studies. J Cardiovasc Mag Reson. 2012; 14(suppl 1): 281.
14. Tham EB, Chow K, Spavor M, Pagano JJ, Haykowsky M, Thompson RB. Degree of diffuse fibrosis measured by MRI correlates with lv remodelling in childhood cancer survivors after anthracycline chemotherapy. J Cardiovasc Mag Reson. 2011; 13(suppl 1): 276.
15. Chow K, Flewitt J, Pagano J, Green J, Friedrich M, Thompson RB. Characterization of myocardial t1 and partition coefficient as a function of time after gadolinium delivery in healthy subjects. J Cardiovasc Mag Reson. 2011; 13(suppl 1): 31.
16. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG. Myocardial triglycerides and systolic function in humans: in vivoevaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003; 49: 417-423. (Pubitemid 36262808)
17. Rial B, Robson MD, Neubauer S, Schneider JE. Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla. Magn Reson Med. 2011; 66: 619-624.
18. den Hollander JA, Evanochko WT, Pohost GM. Observation of cardiac lipids in humans by localized 1H magnetic resonance spectroscopic imaging. Magn Reson Med. 1994; 32: 175-180. (Pubitemid 24243297)
19. van der Meer RW, Doornbos J, Kozerke S, Schär M, Bax JJ, Hammer S, Smit JW, Romijn JA, Diamant M, Rijzewijk LJ, de Roos A, Lamb HJ. Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology. 2007; 245: 251-257. (Pubitemid 47417809)
20. Cheng-Baron J, Chow K, Khoo NS, Esch BT, Scott JM, Haykowsky MJ, Tyberg JV, Thompson RB. Measurements of changes in left ventricular volume, strain, and twist during isovolumic relaxation using MRI. Am J Physiol Heart Circ Physiol. 2010; 298: H1908-H1918.
21. Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Ariet M. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983; 40: 1016-1019. (Pubitemid 13095552)
22. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005; 7: 775-782. (Pubitemid 41770055)
23. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001; 218: 703-710. (Pubitemid 32172551)
24. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, Kellman P, Jones BL, Ludwig DR, Schwartzman D, Shroff SG, Wong TC. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson. 2011; 13: 16.
25. Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, Sivananthan MU. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med. 2007; 58: 34-40. (Pubitemid 47229915)
26. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/ NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010; 121: 2462-2508.
27. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. J AM COLL CARDIOL. Cardiovasc Imaging. 2011; 4: 592-601.
28. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003; 24: 2151-2155. (Pubitemid 37486535)
29. Weidemann F, Breunig F, Beer M, Sandstede J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005; 26: 1221-1227. (Pubitemid 40863129)
30. Maier SE, Fischer SE, McKinnon GC, Hess OM, Krayenbuehl HP, Boesiger P. Evaluation of left ventricular segmental wall motion in hypertrophic cardiomyopathy with myocardial tagging. Circulation. 1992; 86: 1919-1928.
31. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, Lachmann RH, Murphy E, Mehta A, Hughes DA, McKenna WJ, Taylor AM, Hausenloy DJ, Hawkins PN, Elliott PM, Moon JC. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012; 98: 1436-1441.
32. Vanhecke TE, Gandhi M, McCullough PA, Lazar MH, Ravikrishnan KP, Kadaj P, Begle RL. Outcomes of patients considered for, but not admitted to, the intensive care unit. Crit Care Med. 2008; 36: 812-817.
33. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013; 6: 392-398.
34. Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, Shah J, Lee P, Elliott P. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol. 2010; 19: 293-301.
35. Elleder M, Bradová V, Smíd F, Buděsí nský M, Harzer K, Kustermann-Kuhn B, Ledvinová J, Bělohlávek, Král V, Dorazilová V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990; 417: 449-455. (Pubitemid 20345820)
36. Petritsch B, Köstler H, Machann W, Horn M, Weng AM, Goltz JP, Hahn D, Niemann M, Weidemann F, Wanner C, Beer M. Non-invasive determination of myocardial lipid content in Fabry disease by 1H-MR spectros-copy. Rofo. 2012; 184: 1020-1025.
37. * in thalassaemia major. J Magn Reson Imaging. Jan 31, 2013. doi: 10.1002/jmri.24010. http://onlinelibrary.wiley.com/doi/10.1002/jmri. 24010/pdf. Accessed June 1, 2013.
38. Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Choudhury RP, Friedrich MG, Robson MD, Neubauer S. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012; 14: 42.
39. Dall'Armellina E, Piechnik SK, Ferreira VM, Si QL, Robson MD, Francis JM, Cuculi F, Kharbanda RK, Banning AP, Choudhury RP, Karamitsos TD, Neubauer S. Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson. 2012; 14: 15.
40. Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, Shah S, Greiser A, Kellman P, Arai AE. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. J AM COLL CARDIOL. Cardiovasc Imaging. 2012; 5: 596-603.
41. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008; 52: 1574-1580.
42. 1 mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study. Circ Cardiovasc Imaging. 2012; 5: 51-59.
43. *2 and T1 measurements. Magn Reson Med. 1999; 41: 686-695. (Pubitemid 29205714)
44. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging. 2007; 26: 1081-1086. (Pubitemid 47548170)
45. Messroghli DR, Plein S, Higgins DM, Walters K, Jones TR, Ridgway JP, Sivananthan MU. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution-reproducibility study. Radiology. 2006; 238: 1004-1012. (Pubitemid 43289933)
46. Nacif MS, Turkbey EB, Gai N, Nazarian S, van der Geest RJ, Noureldin RA, Sibley CT, Ugander M, Liu S, Arai AE, Lima JA, Bluemke DA. Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences. J Magn Reson Imaging. 2011; 34: 1367-1373.
47. Sparrow P, Messroghli DR, Reid S, Ridgway JP, Bainbridge G, Sivananthan MU. Myocardial T1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study. AJR Am J Roentgenol. 2006; 187: W630-W635.
48. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for highresolution T1 mapping of the heart. Magn Reson Med. 2004; 52: 141-146. (Pubitemid 39295266)
49. Piechnik SK, Ferreira VM, Lewandowski AJ, Ntusi NA, Banerjee R, Holloway C, Hofman MB, Sado DM, Maestrini V, White SK, Lazdam M, Karamitsos T, Moon JC, Neubauer S, Leeson P, Robson MD. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiovasc Magn Reson. 2013; 15: 13.
50. Lu H, Clingman C, Golay X, van Zijl PC. Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla. Magn Reson Med. 2004; 52: 679-682. (Pubitemid 39108984)
51. Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen PS, Hasholt L, Nørremølle A, Feldt-Rasmussen U, Køber L, Bundgaard H. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail. 2010; 12: 535-540.
52. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007; 116: 1170-1175. (Pubitemid 47360218)